SELECT PUBLICATIONS
Colucci G et al. Phase III randomized trial of FOLFIRI versus FOLFOX4 in the treatment
of advanced colorectal cancer: A multicenter study of the Gruppo Oncologico
Dell’Italia Meridionale. J Clin Oncol 2005;23(22):4866-75. Abstract
Diaz-Rubio E, Schmoll HJ. The future development of bevacizumab in colorectal cancer.
Oncology 2005;69(Suppl 3):34-45. Abstract
Ferrara N et al. Bevacizumab (Avastin), a humanized anti-VEGF monoclonal antibody
for cancer therapy. Biochem Biophys Res Commun 2005;333(2):328-35. Abstract
Hoff PM et al. Preliminary results of a phase II study of FOLFORI plus bevacizumab
as first-line treatment for metastatic colorectal cancer (mCRC). Proc ASCO GI Cancers
Symposium 2006;Abstract 252.
Hurwitz H et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for
metastatic colorectal cancer. N Engl J Med 2004;350(23):2335-42. Abstract
Hurwitz H. Integrating the anti-VEGF-A humanized monoclonal antibody bevacizumab
with chemotherapy in advanced colorectal cancer. Clin Colorectal Cancer 2004;4(Suppl
2):62-8. Abstract
Tournigand C et al. OPTIMOX1: A randomized study of FOLFOX4 or FOLFOX7 with
oxaliplatin in a stop-and-go fashion in advanced colorectal cancer — A GERCOR
study. J Clin Oncol 2006;24(3):394-400. Abstract
